High frequency of primary mutations associated with antiretroviral drug resistance in recently diagnosed HIV-infected children

Antiviral Therapy

Volumn 12, Issue 7, 2007, Pages 1133-1137

  Vignoles, Moira ^a   Barboni, Graciela ^b   Agosti, María Rosa ^c   Quarleri, Jorge ^a   García, Mariel Karina ^c   Giraudi, Vera ^b   Ayala, Silvia González ^c   Salomón, Horacio ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b HOSPITAL GENERAL DE NIÑOS PEDRO DE ELIZALDE   (Argentina)

^c Hospital de Ninos Sor Maria Ludovica   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ADOLESCENT; ARTICLE; CHILD; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; GENE SEQUENCE; HEALTH CARE SYSTEM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MOTHER; MUTATION RATE; NEWBORN SCREENING; NUCLEOTIDE SEQUENCE; PEDIATRIC HOSPITAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; VERTICAL TRANSMISSION; VIRUS STRAIN; VIRUS TYPING;

ADOLESCENT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, VIRAL; FEMALE; HIV; HIV INFECTIONS; HUMANS; INFANT; MALE; MOLECULAR SEQUENCE DATA; MUTATION; PROSPECTIVE STUDIES;

EID: 36148989153     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Sperling RS, Shapiro DE, Coombs RW, et al. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1996; 335:1621-1629.
2. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994; 331:1173-1180.
3. World Health Organization. Antiretroviral therapy of HIV infection in infants and children in resource-limited settings: towards universal access. Geneva: World Health Organization 2006; pp. 1-2. Available at http://aidsinfo.nih.gov/ContentFiles/PediatricGuidelines.pdf. Accessed 28 March 2007.
4. Dabis F, Bequet L, Ekouevi DK, et al. Field efficacy of zidovudine, lamivudine and single-dose nevirapine to prevent peripartum HIV transmission. AIDS 2005; 19:309-318.
5. Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the use of antiretroviral agents in pediatric HIV infection. October 26, 2006; pp. 1-5. Available at http://aidsinfo.nih.gov/ContentFiles/PediatricGuidelines.pdf. Accessed 28 March 2007.
6. Descamps D, Flandre P, Calvez V, et al. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. JAMA 2000; 283:205-211.
7. Havlir DV, Hellmann NS, Petropoulos CJ, et al. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. JAMA 2000; 283:229-234.
8. Aboulker JP, Babiker A, Chaix ML, et al. Highly active antiretroviral therapy started in infants under 3 months of age: 72-week follow-up for CD4 cell count, viral load and drug resistance outcome. AIDS 2004; 18:237-245.
9. Eshleman SH, Hoover DR, Chen S, et al. Resistance after single-dose nevirapine prophylaxis emerges in a high proportion of Malawian newborns. AIDS 2005; 19:2167-2169.
10. Parker MM, Wade N, Lloyd RM Jr, et al. Prevalence of genotypic drug resistance among a cohort of HIV-infected newborns. J Acquir Immune Defic Syndr 2003; 32:292-297.
11. Paediatric European Network for Treatment of AIDS (PENTA). Five year follow up of vertically HIV infected children in a randomised double blind controlled trial of immediate versus deferred zidovudine: the PENTA 1 trial. Arch Dis Child 2001; 84:230-236.
12. Palumbo P, Holland B, Dobbs T, et al. Antiretroviral resistance mutations among pregnant human immunodeficiency virus type 1-infected women and their newborns in the United States: vertical transmission and clades. J Infect Dis 2001; 184:1120-1126.
13. Masquelier B, Chaix ML, Burgard M, et al. Zidovudine genotypic resistance in HIV-1-infected newborns in the French perinatal cohort. J Acquir Immune Defic Syndr 2001; 27:99-104.
14. Jackson JB, Becker-Pergola G, Guay LA, et al. Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission. AIDS 2000; 14:F111-F115.
15. Eshleman SH, Mracna M, Guay LA, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS 2001; 15:1951-1957.
16. UNAIDS/WHO. AIDS Epidemic Update (UNAIDS/05.19E). Geneva: UNAIDS 2005; pp. 2-5. Available from http://www.unaids.org/epi/2005/doc/EPIupdate2005_pdf_en/ epi-update2005_en.pdf
17. Little S. Is transmitted drug resistance in HIV on the rise? It seems so. BMJ 2001; 322:1074-1075.
18. Wade NA, Zielinski MA, Butsashvili M, et al. Decline in perinatal HIV transmission in New York State (1997-2000). J Acquir Immune Defic Syndr 2004; 36:1075-1082.
19. Boletín sobre VIH/SIDA en la Argentina: Ministerio de Salud y Ambiente de la Nación [Bulletin of HIV/AIDS in Argentina: National Health and Environment Ministry. Updated December 2005; accessed 1 June 2007]; pp. 27-29. Available at http://www.msal.gov.ar/htm/site/sida/site/pdf/ BoletinSIDAN24X.pdf.
20. Centers for Disease Control and Prevention. 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age. MMWR 1994; 43(RR-12):1-10.
21. Gomez-Carrillo M, Quarleri JF, Rubio AE, et al. Drug resistance testing provides evidence of the globalization of HIV type 1: a new circulating recombinant form. AIDS Res Hum Retroviruses 2004; 20:885-888.
22. Stanford University. HIVdb: Genotypic resistance interpretation algorithm. Available at http://hivdb6.stanford.edu/asi/deployed/hiv_central.pl? program=hivdb&action=showSequenceForm [updated 12 July 2007; accessed 1 June 2007].
23. Los Alamos National Laboratory. HIV-1 subtype reference alignments [updated 2005; cited February 2006]. Available from http://www.hiv.lanl.gov/ content/hiv-db/SUBTYPE_REF/align.html
24. Hall T. Bioedit: a user-friendly biological sequence editor and analysis program for Windows 95/98/NT. Nucl Acids Symp Ser 1999; 41:95-98.
25. Lole KS, Bollinger RC, Paranjape RS, et al. Full-length human immunodeficiency virus type 1 genomes from subtype-C-infected seroconverters in India, with evidence of intersubtype recombination. J Virol 1999; 73:152-160.
26. World Health Organization. Guidelines for Surveillance of HIV Drug Resistance. Geneva: World Health Organization 2003. Available from http://wwwn.cdc.gov/dls/ila/cd/whoafro/resisguide12_12.pdf
27. Kijak GH, Pampuro SE, Avila MM, et al. Resistance profiles to antiretroviral drugs in HIV-1 drug-naive patients in Argentina. Antivir Ther 2001; 6:71-77.
28. Petroni A, Deluchi G, Pryluka D, et al. Update on primary HIV-1 resistance in Argentina: emergence of mutations conferring high-level resistance to nonnucleoside reverse transcriptase inhibitors in drug-naive patients. J Acquir Immune Defic Syndr 2006; 42:506-510.
29. Dilernia DA, Lourtau L, Gomez AM, et al. Drug-resistance surveillance among newly HIV-1 diagnosed individuals in Buenos Aires, Argentina. AIDS 2007; 21:1355-1360.
30. Karchava M, Pulver W, Smith L, et al. Prevalence of drug-resistance mutations and non-subtype B strains among HIV-infected infants from New York State. J Acquir Immune Defic Syndr 2006; 42:614-619.
31. Persaud D, Palumbo P, Ziemniak C, et al. Early archiving and predominance of nonnucleoside reverse transcriptase inhibitor-resistant HIV-1 among recently infected infants born in the United States. J Infect Dis 2007; 195:1402-1410.
32. Hirsch MS, Brun-Vezinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 2003; 37:113-128.
33. Vandamme AM, Sonnerborg A, Ait-Khaled M, et al. Updated European recommendations for the clinical use of HIV drug resistance testing. Antivir Ther 2004; 9:829-848.